StockFame
  • Trending News
  • Markets
  • US Markets
  • Indian Stocks
  • Economics
  • Crypto News
Select Page

Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients

by CNBC Markets | August 18, 2025 7:23 pm | US Markets

Patients can pay $499 in cash per month for three dose sizes of Ozempic through the company’s direct-to-consumer pharmacy and GoodRx, among other platforms.

Recent Posts

  • Corporate America Is Crushing All Estimates – But Magnificent Seven Still Run The Show
  • Simulation Software Market Surges to $36.22 billion by 2030 – Dominated by Dassault Systemes (France), Ansys (US), Autodesk (US)
  • Inventory Optimization Market Poised for Significant Growth, Estimate to Hit USD 12.42 Billion by 2032 | Coherent Market Insights
  • Ambulance Vehicles Market Poised for Explosive Growth, Projected to Hit USD 31.43 Billion by 2032 | Coherent Market Insights
  • Solar Water Pump Systems Market Poised for Growth, Expected to Hit USD 5.76 Billion by 2032 | Coherent Market Insights

About Stockfame

Stockfame is a global media platform delivering bold insights on business, markets, technology, leadership, and entrepreneurship. We bring you research-backed news and sharp analysis to help you stay ahead of the curve.

Quick News Links

  • Crypto News
  • Indian Stocks
  • Latest Posts
  • Market
  • News
  • Trending News
  • US Markets

Contact Us

Reach out to us at:
Phone:  [+91] 9834938257
Email: contact@stockfame.com
For Advertisement, Press Releases, Partnerships or to get backlinks on this website, please e-mail us at contact@stockfame.com

Quick Reads

  • Global market news
  • Crypto Market News
  • Indian Market News
  • Economy News
  • Latest Business News
  • About
  • Terms and Conditions
  • Privacy Policy
  • Website User Agreement
  • Disclaimer
  • Facebook
  • X
  • Instagram
  • RSS
Copyright @StockFame | All Rights Reserved